Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 3, 2010, Pages 670-676

  Weiler, Markus ^a,c   Hartmann, Christian ^d   Wiewrodt, Dorothee ^e   Herrlinger, Ulrich ^f   Gorlia, Thierry ^g   Bähr, Oliver ^a   Meyermann, Richard ^b   Bamberg, Michael ^b   Tatagiba, Marcos ^b   von Deimling, Andreas ^c   Weller, Michael ^a,h   Wick, Wolfgang ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g European Organisation of Research and Treatment of Cancer   (Belgium)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Glioblastoma; indomethacin; MGMT; O6 methylguanine DNA methyltransferase; radiotherapy; temozolomide

Indexed keywords

ALKYLATION; CHEMORADIOTHERAPY; DISEASES; GENES; RADIOTHERAPY;

GLIOBLASTOMAS; INDOMETHACIN; METHYLTRANSFERASES; MGMT; TEMOZOLOMIDE;

TOXICITY;

INDOMETACIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DNA METHYLATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GLIOBLASTOMA; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYGROMA; ILEUS; INTESTINE PERFORATION; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; STOMACH PAIN; SURVIVAL RATE; THROMBOCYTOPENIA; TOXIC HEPATITIS; TUMOR BLEEDING; UNSPECIFIED SIDE EFFECT; VIRUS PNEUMONIA;

EID: 77952571590     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.031     Document Type: Article

References (24)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Gerson S.L. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4 (2004) 296-307
3. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
4. Tolcher A.W., Gerson S.L., Denis L., et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003) 1004-1011
5. Tosoni A., Cavallo G., Ermani M., et al. Is protracted low-dose temozolomide feasible in glioma patients?. Neurology 66 (2006) 427-429
6. Wick A., Felsberg J., Steinbach J.P., et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25 (2007) 3357-3361
7. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (2000) 588-593
8. Choy H., and Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance?. J Natl Cancer Inst 95 (2003) 1440-1452
9. Lundholm K., Gelin J., Hyltander A., et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54 (1994) 5602-5606
10. Bradbury C.M., Markovina S., Wei S.J., et al. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res 61 (2001) 7689-7696
11. Sengupta S., Sellers L.A., Cindrova T., et al. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Res 63 (2003) 8351-8359
12. Shono T., Tofilon P.J., Bruner J.M., et al. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61 (2001) 4375-4381
13. Combs S.E., Gutwein S., Schulz-Ertner D., et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme: Phase I/II study. Strahlenther Onkol 181 (2005) 372-377
14. MacDonald D.R., Cascino T.L., Schold Jr. S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
15. Kaplan E., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
16. Gorlia T., van den Bent M.J., Hegi M.E., et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9 (2008) 29-38
17. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
18. Stupp R., Goldbrunner R., Neyns B., et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma [Abstract]. J Clin Oncol 25 Suppl. (2007) 18S
19. Herrlinger U., Rieger J., Koch D., et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24 (2006) 4412-4417
20. Mirimanoff R.O., Gorlia T., Mason W., et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24 (2006) 2563-2569
21. Neyns B., van Mierlo B., Menten J., et al. A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo)astrocytoma: An interim analysis of toxicity [Abstract]. J Clin Oncol 23 Suppl. (2005) 16S
22. Brandes A.A., Tosoni A., Cavallo G., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer 95 (2006) 1155-1160
23. Chinot O.L., Barrie M., Fuentes S., et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25 (2007) 1470-1475
24. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23 (2005) 2372-2377